Pain · 2017 · 75 citations · 40 references
MedicineOncologyPharmacologyBone MetabolismPain MedicineSignal TransductionCancer PainNeuropathic PainPain MechanismsPain ModulationPain NeurobiologyPain NeuroscienceBone Pain In CancerCancer Pain PathophysiologyCancer Pain SyndromesInflammation-pain CouplingLipid Metabolism AlterationsNeuropathic ChangesPain Mechanisms In CancerSphingolipid Biosynthesis
Metastatic bone pain is the single most common form of cancer pain and persists as a result of peripheral and central inflammatory, as well as neuropathic mechanisms. Here, we provide the first characterization of sphingolipid metabolism alterations in the spinal cord occurring during cancer-induced bone pain (CIBP). Following femoral arthrotomy and syngenic tumor implantation in mice, ceramides decreased with corresponding increases in sphingosine and the bioactive sphingolipid metabolite, sphingosine 1-phosphate (S1P). Intriguingly, de novo sphingolipid biosynthesis was increased as shown by the elevations of dihydro-ceramides and dihydro-S1P. We next identified the S1P receptor subtype 1 (S1PR1) as a novel target for therapeutic intervention. Intrathecal or systemic administration of the competitive and functional S1PR1 antagonists, TASP0277308 and FTY720/Fingolimod, respectively, attenuated cancer-induced spontaneous flinching and guarding. Inhibiting CIBP by systemic delivery of FTY720 did not result in antinociceptive tolerance over 7 days. FTY720 administration enhanced IL-10 in the lumbar ipsilateral spinal cord of CIBP animals and intrathecal injection of an IL-10 neutralizing antibody mitigated the ability of systemic FTY720 to reverse CIBP. FTY720 treatment was not associated with alterations in bone metabolism in vivo. Studies here identify a novel mechanism to inhibit bone cancer pain by blocking the actions of the bioactive metabolites S1P and dihydro-S1P in lumbar spinal cord induced by bone cancer and support potential fast-track clinical application of the FDA-approved drug, FTY720, as a therapeutic avenue for CIBP.
40
Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1
Mehrdad Matloubian, Charles G. Lo, Guy Cinamon et al. · Nature · 2004 · 2.5K citations
The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors
Volker Brinkmann, Michael D. Davis, Christopher E. Heise et al. · Journal of Biological Chemistry · 2002 · 1.5K citations · Full text
Medicine, Immunology, Pharmacology +17
Russell K. Portenoy, Pauline Lesage · The Lancet · 1999 · 1K citations
Medicine, Oncology, Oncology Nursing +12
Heritability of nociception I: Responses of 11 inbred mouse strains on 12 measures of nociception
Jeffrey S. Mogil, Sonya G. Wilson, Karine Bon et al. · Pain · 1999 · 658 citations
An international survey of cancer pain characteristics and syndromes
Augusto Caraceni, Russell K. Portenoy · Pain · 1999 · 623 citations
Medicine, Oncology, Pain Management +15